The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

The U.S. FDA has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified ...

Mum claims GP said her four-year-old was ‘faking it’ week before leukaemia diagnosis - Summer’s mum is warning other parents to ‘trust their instinct’ ...

A groundbreaking study has uncovered molecular markers in blood at birth that are linked to later development of acute ...

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

“With the U.S. Food and Drug Administration (FDA) having approved AUCATZYL ® (obe-cel) for the treatment of adult B-cell Acute Lymphoblastic Leukemia (B-ALL) patients, we are all systems go with our ...

IN A breakthrough study, researchers have reported encouraging outcomes using autologous chimeric antigen receptor (CAR) T ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.